Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease: A Southwest Oncology Group phase II study

T. P. Miller, S. E. Jones, J. M. Rainey

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The CHOP combination is active as evidenced by the objective response rate of 100% obtained in this study of patients with advanced HD. It is interesting that despite the low CR rate obtained with CHOP, seven of 12 patients are currently free of disease after having received MOPP following tumor-burden reduction with CHOP. Such an observation may warrant a trial of CHOP alternating with MOPP as initial treatment for advanced HD.

Original languageEnglish (US)
Pages (from-to)739-740
Number of pages2
JournalCancer Treatment Reports
Volume67
Issue number7-8
StatePublished - Dec 1 1983

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with advanced Hodgkin's disease: A Southwest Oncology Group phase II study'. Together they form a unique fingerprint.

  • Cite this